Description
Human Pluripotent Stem Cells (hPSCs), organoids, and advanced bioimaging are transforming human in vitro model systems in biomedical research. These technologies are anticipated to form the cornerstone of effective and safe preclinical trials and future cellular therapies. However, their full potential remains constrained by technical limitations.
STEMPREDICT is a groundbreaking initiative addressing a critical challenge in biomedical research: efficiently and non-invasively assessing the phenotype, health, and quality of pluripotent stem cells, differentiated cells, and organoid systems. These cell-based models are essential for advancing therapies and deepening our understanding of diseases. However, traditional monitoring techniques are often slow, labour-intensive, and unsuitable for large-scale experimental setups.
By integrating imaging technologies with artificial intelligence (AI), STEMPREDICT aims to develop tools capable of real-time cell analysis. These tools will extract valuable phenotypic information by analysing label free imaging data eliminating the need for destructive testing methods and enhancing the potential to further automate cell production.
This innovative approach will enhance the optimization of stem cell production and improve predictions about their suitability as disease or therapeutic models, delivering unprecedented efficiency.
By benefiting from high-level experts and data from EU Core Facilities, the platform developed within STEMPREDICT ensures wide adoption, fast implementation, and broad accessibility across Europe and beyond. It strengthens European research infrastructures and establishes global standards for quality control in stem cell-based research.
Action keywords
AI-powered imaging - Pluripotent stem cells - Label-free phase-contrast microscopy - European core facilities
Main Contacts
Action Contacts
COST Staff
Leadership
| Role | Leader |
|---|---|
| Action Chair | |
| Action Vice-Chair |